174 related articles for article (PubMed ID: 36006771)
41. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
[TBL] [Abstract][Full Text] [Related]
42. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
43. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
[TBL] [Abstract][Full Text] [Related]
44. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
45. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
[TBL] [Abstract][Full Text] [Related]
48. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
[TBL] [Abstract][Full Text] [Related]
49. Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.
Shen Z; Wang L; Zhang B; Li T; Li D; He C; Xue Y; Wang Y; Li B; Liu Q; Zhang H; Gu W; Wang F; Wang C; Shi Y; Ye J; Zhu T; Miao Y; Huang S; Sang W
Front Oncol; 2021; 11():754180. PubMed ID: 34804942
[TBL] [Abstract][Full Text] [Related]
50. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
Gualco G; Weiss LM; Harrington WJ; Bacchi CE
Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
[TBL] [Abstract][Full Text] [Related]
51. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
52. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
[TBL] [Abstract][Full Text] [Related]
53. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
54. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
[TBL] [Abstract][Full Text] [Related]
55. Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
Agostinelli C; Morandi L; Righi S; Cirillo L; Iommi M; Tonon C; Mazzatenta D; Zoli M; Rossi M; Bagnato G; Broccoli A; Lodi R; Zinzani PL; Sabattini E; Giannini C; Asioli S
Mod Pathol; 2023 Dec; 36(12):100323. PubMed ID: 37678673
[TBL] [Abstract][Full Text] [Related]
56. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
57. CD5+ diffuse large B-cell lymphoma: a narrative review.
Durani U; Ansell SM
Leuk Lymphoma; 2021 Dec; 62(13):3078-3086. PubMed ID: 34284686
[TBL] [Abstract][Full Text] [Related]
58. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
[TBL] [Abstract][Full Text] [Related]
59. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
60. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]